D2B3
PrivateLast Round
Pre Seed
Jun 1, 2024
Total Funding Raised
$500,000
Company Overview
D2B3 is a biotechnology company that operates a pre-clinical platform intended to advance drug delivery to the brain and central nervous system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
D2B3 Comparables
Compare D2B3 with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Qinotto, Inc. | 83% | |
| Gate2Brain | 82% | |
| Sylamore Bio | 76% | |
D2B3 Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Pre Seed | Jun 1, 2024 |
D2B3 Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Connecticut Innovations | Pre Seed |
| Alexandria LaunchLabs | Pre Seed |
| Yale Ventures | Pre Seed |
| Mission BioCapital | Pre Seed |
| SOSV | Pre Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2024
$500K round led by Mission BioCapital.
D2B3 Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about D2B3's valuation, stock price, and market status.